• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) >The Construction and The Biosafety Research of A DNA Vaccine pPCV-HP Against Taenia solium cysticercosis
【24h】

The Construction and The Biosafety Research of A DNA Vaccine pPCV-HP Against Taenia solium cysticercosis

机译：DNA疫苗pPCV-HP抗猪带en虫囊尾rc病的构建及生物安全性研究

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our previous study has confirmed that the fragment of HPREαβ1 in HBV genome could obviously improve the gene expression in the post-transcriptional level. In our present study, we constructed a DNA vaccine pPCV-HP, and studied the protection and biosafety of this vaccine. We constructed the new vaccine by inserting the fragment of HPREαβ1 into the downstream of the gene pPCV which is located in the DNA vaccine against cysticercosis. After inoculation to BALB/c mice with pPCV-HP, antibody titers were assayed by ELISA and the mice were performed challenge with the infectious T.solium eggs. Numbers of cysticercus were calculated after three months. Pigs were immunized with the new vaccine using intramuscular injection. Different tissues were separated and the total DNA were extracted from tissues. Then the distribution of the DNA vaccine in different tissues and the possibility of DNA vaccine integration into the host genome were analyzed by PCR. Meanwhile, the environment samples were collected, the transformation and diffusion possibility of CMV promoter gene, kanamycin resistance gene and antigen gene into the environment was analyzed by PCR. Results showed that the antibody titers and the protective rate after immunized with DNA vaccine pPCV-HP were obviously higher than the immunity group of pPCV. The integration of DNA vaccine into host genome and the transformation to environment were not observed in sensitivity of 30 copies. All these revealed that DNA vaccine pPCV-HP has high protective rate and biosafety.
机译：我们先前的研究已经证实，HBV基因组中的HPREαβ1片段可以明显改善转录后水平的基因表达。在本研究中，我们构建了DNA疫苗pPCV-HP，并研究了该疫苗的保护和生物安全性。我们通过将HPREαβ1片段插入位于抗囊尾rc病DNA疫苗中的pPCV基因的下游来构建新疫苗。用pPCV-HP接种BALB / c小鼠后，通过ELISA测定抗体滴度，并用感染性T.solium卵攻击小鼠。三个月后计算出囊性膀胱的数目。通过肌肉注射用新疫苗对猪进行免疫。分离不同的组织，并从组织中提取总DNA。然后通过PCR分析了DNA疫苗在不同组织中的分布以及DNA疫苗整合入宿主基因组的可能性。同时，收集环境样品，通过PCR分析CMV启动子基因，卡那霉素抗性基因和抗原基因向环境的转化和扩散可能性。结果表明，DNA疫苗pPCV-HP免疫后的抗体效价和保护率明显高于pPCV免疫组。 DNA疫苗整合到宿主基因组中和向环境的转化未发现30份的敏感性。所有这些表明，DNA疫苗pPCV-HP具有很高的保护率和生物安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号